Core Viewpoint - The article highlights the recent achievement of Yi Yang Qianxi, who won the Best Actor award at the 38th China Golden Rooster Awards for his role in "Little Me," making him the youngest recipient of this award at the age of 24 [1][3]. Group 1: Awards and Recognition - Yi Yang Qianxi has been nominated four times for the Best Actor award at the Golden Rooster Awards, with this win marking a significant milestone in his career [1][3]. - The Central Academy of Drama congratulated Yi Yang Qianxi on his achievement, emphasizing his status as the youngest Golden Rooster Best Actor [1][3]. Group 2: Box Office Performance - The total box office revenue for films starring Yi Yang Qianxi has reached 19.7 billion [5]. Group 3: Business Associations - Yi Yang Qianxi is directly associated with two companies: Beijing Jiumude Cultural Development Co., Ltd. and Beijing Jiumude Cultural Media Center, the latter of which has been deregistered [6]. - Beijing Jiumude Cultural Development Co., Ltd. was established in December 2018, with Yi Yang Qianxi and Yi Shangjie each holding a 50% stake; Yi Shangjie is identified as Yi Yang Qianxi's father [6]. - Yi Yang Qianxi's associated company, Beijing Yangzhizhu Cultural Media Co., Ltd., has registered multiple trademarks and websites, although he does not hold direct shares in this company [6]. Group 4: Endorsements - Yi Yang Qianxi endorses over ten brands, including Li Xiang Automobile, Proya, Luckin Coffee, Huawei Nova, and Fila [6].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 112.46 CNY [3][7]. Core Insights - The company reported better-than-expected earnings in Q1, with significant growth from emerging brands [1]. - Revenue and net profit for 2024 are projected to be 10.778 billion CNY and 1.552 billion CNY, respectively, reflecting year-on-year growth of 21% and 30% [6]. - The company is expected to continue expanding its brand portfolio and market share in various segments, including men's skincare and medical post-operative recovery [6]. Financial Forecasts - The adjusted earnings per share (EPS) estimates for 2025-2027 are 4.56 CNY, 5.36 CNY, and 6.06 CNY, respectively [2][7]. - The company's revenue is forecasted to grow from 8.905 billion CNY in 2023 to 15.577 billion CNY in 2027, with a compound annual growth rate (CAGR) of approximately 10.7% [2][10]. - The gross margin is expected to improve from 69.9% in 2023 to 73.0% in 2027, indicating enhanced profitability [2][10]. Brand Performance - The main brand and the Cai Tang brand showed stable performance, while emerging brands like OR and Yuan Se Bo Ta experienced rapid growth, with revenue increases of 71.1% and 138.4%, respectively [6]. - Online sales channels grew by 23.7% in 2024, while offline channels saw a decline of 13.6% [6]. Market Position - The company has demonstrated resilience in a challenging consumer environment, maintaining strong performance across its brand matrix [6]. - The report highlights the company's ability to adapt and thrive despite market pressures, positioning it well for future growth [6].